Topic: non-small cell lung cancer
The readout suggests that, if anything, adding tremelimumab to PD-L1 drug Imfinzi results in worse outcomes in metastatic NSCLC.
South Korea’s Yuhan has licensed its lung cancer drug lazertinib to Janssen Biotech for $50 million upfront and another $1.2 billion in milestones.
The setback, Merrimack Pharmaceuticals' second flop in four months, wiped 35% off the company’s stock and left its rebooted strategy in tatters.
Ziopharm Oncology’s executive vice president of R&D, Francois Lebel, M.D., is moving to cancer drugmaker Spectrum Pharmaceuticals effective Nov. 5.
TP Therapeutics netted $80 million and a new CEO as it looks to move its lead candidate in drug-resistant tumors into phase 2 early next year.
The FDA approved Qiagen’s Therascreen EGFR kit as a companion diagnostic for Pfizer’s Vizimpro, to identify NSCLC patients with specific mutations.
Two dual EGFR/HER2 inhibitors from Boehringer Ingelheim and Puma showed in vitro activity against AML cancer cells.
Early data showed that Blueprint's RET inhibitor and AstraZeneca’s Tagrisso could potentially beat treatment resistance in NSCLC patients.
The FDA cleared Roche’s cobas EGFR test for use as a companion diagnostic for AstraZeneca’s Iressa in first-line non-small cell lung cancer.
After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.